• Rev Neurol France · Jun 2004

    Review

    [Surgical treatment of epilepsy: outcome of various surgical procedures in adults and children].

    • M Guénot.
    • Service de Neurochirurgie et Stéréotaxie Fonctionnelles (Pr Sindou), Hôpital P. Wertheimer, 59 Boulevard Pinel, 69003 Lyon, France. marc.guenot@chu-lyon.fr
    • Rev Neurol France. 2004 Jun 1; 160 Spec No 1: 5S241-50.

    AbstractSurgical treatment of drug-resistant epilepsy is being performed in a growing number of adults and children. The objective of this report is to review and evaluate the published literature related to the outcome of epilepsy surgery. Surgical procedures were classified as "curative", which included temporal and extratemporal resections, as well as hemispherotomy and stereotactic radiosurgery, and as "palliative", which mainly included callosotomy and multiple subpial transections. Data obtained from the literature suggest that after temporal lobe surgery, 68 percent of the adult patients, on average, are seizure-free. This result may vary, according to the authors, from 50 to 93 percent. One randomized controlled study concludes that 58 percent of patients treated surgically become seizure-free, compared to only 8 percent in the group of patients who do not receive surgery. This suggests that temporal lobe surgery is an efficient treatment of drug-refractory temporal lobe surgery. Seizure outcome is similar in the pediatric population. Studies of frontal lobe surgery report that an average of 60 percent of patients are seizure-free after surgery, in adults as well as in children. These results may vary considerably, depending on how the seizure outcome is defined. Too few studies are available to allow for an evaluation of parietal or occipital lobe surgery. Hemispherotomy is mostly performed in the pediatric population. Studies of this procedure report that 60 percent of patients become seizure free after surgery, whereas 80 percent are improved in terms of seizure outcome and in terms of behavior. Stereotactic radiosurgery may be performed in case of hypothalamic hamartoma, and in some cases of temporal lobe epilepsy. In this later case, the reported results are similar to those obtained with temporal resections. Seizure outcome after corpus callosotomy is difficult to summarize, because of the many variations, according to the authors, of the definition of a good or poor seizure outcome. However, it can be stated that 65 to 85 percent of patients achieve a significant reduction in overall seizure frequency. The best reduction in seizure frequency is achieved in patients with atonic. Reported percentages of patients who benefit from multiple subpial transection, varies between 50 and 70 percent. In conclusion, our report shows that temporal resection is an efficient and scientifically validated treatment of drug-resistant temporal lobe epilepsy. Extra-temporal resections, hemispherotomy, and palliative surgery often allow cure of epilepsy, or a decrease of seizure frequency, however, prospective studies of these surgical procedures are needed.

      Pubmed     Full text   Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…

What will the 'Medical Journal of You' look like?

Start your free 21 day trial now.

We guarantee your privacy. Your email address will not be shared.